2026 Student Research Conference:
39th Annual Student Research Conference

Program

Program-At-A-Glance

8:00 AM - 5:00 PM • 
Asynchronous Virtual Presentations

8:30 - 9:45 • MG 2001
SESSION 106-
MG 2001 8:30 -

Presiding:

9:00

106- - 3  WILLOW C. REESE
Dr. Bill R. Miller (A.T. Still University) and Dr. R. Drew Sieg, Faculty Mentors

Computational analysis of the Factor V Leiden mutation and binding differences with Activated Protein C

Add To Custom Schedule (select "Update" button below)

9:15

106- - 4  ADISON P. MOSHER* and HANNAH E. RODRIGUEZ
Dr. Daniela Ostrowski (A.T. Still University) and Dr. Stephen Hudman, Faculty Mentors

Proteomics Analysis of Rats' Hippocampus Tissue Following Repeated Mild Hypoxia

 

Add To Custom Schedule (select "Update" button below)

8:30 - 9:45 • MG 1098
SESSION 108-
MG 1098 8:30 -

Presiding:

8:30

108- - 1  GAGE J. DUDKOWSKI
Dr. Andrew Kauffmann and Dr. Bill R. Miller (A.T. Still University), Faculty Mentors

Inhibition of the Amyloid-Beta Protein Aggregation with Polyphenol Drugs using Computational Chemistry

Add To Custom Schedule (select "Update" button below)

8:45

108- - 2  DAGMAWIT KEBEDE
Dr. Andrew Kauffmann and Dr. Bill R. Miller (A.T. Still University), Faculty Mentors

Allosteric inhibition of Matrix Metalloproteinase 9 (MMP-9) in silico as a potential cancer therapeutic

Add To Custom Schedule (select "Update" button below)

9:00

108- - 3  AUDREY BROWN
Dr. Bill R. Miller (A.T. Still University) and Dr. Andrew Kauffmann, Faculty Mentors

Computational Analysis of Factor V Leiden: APC and Protein S Interactions

Add To Custom Schedule (select "Update" button below)

9:15

108- - 4  MARLAYNA R. LITTLE
Dr. Andrew Kauffmann, Faculty Mentor

Isolation of Tyrosinase from Mushrooms

Add To Custom Schedule (select "Update" button below)

9:30

108- - 5  ABBIE A. WIGGER
Dr. Bill R. Miller (A.T. Still University) and Dr. Andrew Kauffmann, Faculty Mentors

Computational Analysis of Amyloid-Beta Disaggregation Using Polyphenol Ligands

Add To Custom Schedule (select "Update" button below)

10:00 - 11:15 • MG 1000
SESSION 207-
MG 1000 10:00 -

Presiding:

10:15

207- - 2  LAINIE M. MUELLER*, ALEECE WALKER, and MOLLY CERNICH
Dr. Brett A. Berke, Faculty Mentor

Is Cyclophilin 1 the fly version of Cyclophilin D?

Add To Custom Schedule (select "Update" button below)

11:00

207- - 5  ALEECE WALKER* and MOLLY CERNICH
Dr. Brett A. Berke, Faculty Mentor

Cyclophilin 1 mutations alter Drosophila larval crawling

Add To Custom Schedule (select "Update" button below)

10:00 - 11:15 • MG 1098
SESSION 208-
MG 1098 10:00 -

Presiding:

10:00

208- - 1  BYEONGUK CHOI
Dr. Yohei Norimatsu (A. T. Still University) and Dr. Andrew Kauffmann, Faculty Mentors

Neutralization Efficacy of Soluble Angiotensin-Converting Enzyme 2 Against SARS-CoV-2

Add To Custom Schedule (select "Update" button below)

10:15

208- - 2  ISABELLE M. ZAGARRI
Dr. Bill R. Miller (A.T. Still University) and Dr. Andrew Kauffmann, Faculty Mentors

A computational study of the Factor V Leiden mutation and its effect on blood coagulation

Add To Custom Schedule (select "Update" button below)

10:30

208- - 3  JOSEPH M. LAMSON
Dr. Bill R. Miller (A.T. Still University) and Dr. Andrew Kauffmann, Faculty Mentors

Using Computational Methods to Identify Ligands Capable of Promoting the Disaggregation of Lewy Bodies

Add To Custom Schedule (select "Update" button below)

10:45

208- - 4  KAIDEN ZABOROWSKI
Dr. Andrew Kauffmann, Faculty Mentor

Computational investigation of the Human γS-crystallin protein associated with cataracts formation

Add To Custom Schedule (select "Update" button below)

11:45 AM - 12:45 PM • Magruder Hall 2001
Plenary Address - W. David Arnold, MD

W. David Arnold, MD is a physician-scientist and tenured Professor of Physical Medicine & Rehabilitation, Neurology, and Medical Pharmacology & Physiology at the University of Missouri, where he serves as Executive Director of the Roy Blunt NextGen Precision Health Initiative and is a founding leader of the Center for Translational Neurogenetics. With a nontraditional training trajectory that bridges clinical medicine, translational neuroscience, and therapeutic development, his research focuses on translational neuromuscular physiology in the context of health, aging, and disease. His work has helped to define neural contributions to sarcopenia and mechanisms of neuromuscular decline across the lifespan, and his team has published the first efforts to develop neurotherapeutics for the treatment of age-related loss of physical function. Dr. Arnold has contributed to the development of gene-replacement therapy for spinal muscular atrophy (SMA), therapeutic development efforts in Charcot?Marie?Tooth disease (CMT), and advances in genetic and molecular therapies for neuromuscular disorders such as myotonic dystrophy type 1 (DM1). He is the executive director of the NextGen Precision Health Initiative, the largest investment in translational research in the history of the University of Missouri System. He co-directs the MD/PhD program at Missouri, holds national leadership roles in physician-scientist training including the Rehabilitation Medicine Scientist Training Program (RMSTP), chair of the research committee of the AAP, and leads multidisciplinary teams advancing precision therapies for neuromuscular and neurogenetic disease.


1:00 - 2:15 • MG 1000
SESSION 307-
MG 1000 1:00 -

Presiding:

1:00

307- - 1  SUHANI B. PATEL
Dr. Bill R. Miller (A.T. Still University) and Dr. Hanbo Hong, Faculty Mentors

Computational Investigation of Positive Cooperativity in the cMyb-KIX-MLL Ternary Complex

 

Add To Custom Schedule (select "Update" button below)

1:15

307- - 2  HALELUYA T. MERGA
Dr. Anne E. Moody, Faculty Mentor

Computational inhibition of Matrix metalloproteinase 9 (MMP-9) as potential cancer therapeutics

Add To Custom Schedule (select "Update" button below)

1:30

307- - 3  ALEXANDRA M. KLIETHERMES
Dr. Bill R. Miller (A.T. Still University) and Dr. Stephanie Maiden, Faculty Mentors

Computational discovery of a small molecule inhibitor of APOBEC3B as a potential treatment for a variety of cancers

Add To Custom Schedule (select "Update" button below)

2:00

307- - 5  RHICHA RUPAKHETI
Dr. Tim Humphry and Dr. Bill R. Miller (A.T. Still University), Faculty Mentors

Novel Complement Protein 5 Inhibitors as Candidate Therapies for Sepsis

Add To Custom Schedule (select "Update" button below)

1:00 - 2:15 • MG 1098
SESSION 308-
MG 1098 1:00 -

Presiding:

1:00

308- - 1  MOHAMMED AYAN MAHMOOD
Dr. Bill R. Miller (A.T. Still University), Faculty Mentor

Computational Analysis of Small Molecules Targeting Complement Protein 5 (C5) for Treatment of Inflammatory Disorders

Add To Custom Schedule (select "Update" button below)

1:15

308- - 2  DAGMAWIT KEBEDE
Dr. Brett A. Berke and Dr. Bill R. Miller (A.T. Still University), Faculty Mentors

Developing novel inhibitors for Striatal-Enriched Tyrosine Phosphatase (STEP) using computational methods

Add To Custom Schedule (select "Update" button below)

2:30 - 3:30  • Activities Room
SESSION 400-
Poster Session -

400- - 21

RACHEL N. RUSHMAN
Dr. Daniela Ostrowski (A.T. Still University) and Dr. Brett A. Berke, Faculty Mentors

CRLF3 Expression in Rat Brains

Add To Custom Schedule (select "Update" button below)

400- - 24

MAKDA GEBREEGZIABHER*, DAGMAWIT KEBEDE, and HALELUYA T. MERGA
Dr. Andrew Kauffmann, Faculty Mentor

Computational Design of Matrix Metalloproteinase-9 (MMP-9) Inhibitors as Potential Cancer Therapeutics

Add To Custom Schedule (select "Update" button below)

4:00 - 5:00 PM • Ophelia Parrish Art Gallery
Studio Art Reception

   SRC Privacy Policy